Verona Pharma plc Verona Pharma Plc : Pdmr Dealing

 
TIDMVRP TIDMVRP 
 
 
   LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on November 29, 2017, Dr. 
David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 
ordinary shares of 5 pence each in the Company (the "Ordinary Shares") 
at a price of 106.85 pence per Ordinary Share.  Following the 
acquisition, Dr. Ebsworth will have an interest in the Company of 
135,787 Ordinary Shares, representing 0.13% of the Company's issued 
share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
a)  Name                                David Ebsworth 
2   Reason for the notification 
a)  Position/status                     Non-Executive Chairman 
b)  Initial notification/Amendment      Initial notification 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                                Verona Pharma plc 
b)  LEI                                 213800EVI6O6J3TIAL06 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
a)  Description of the financial        Ordinary Shares of 5 pence each 
    instrument, type of instrument 
 
    Identification code                 GB00BYW2KH80 
 
b)  Nature of the transaction           David Ebsworth purchased 10,000 
                                        Ordinary Shares 
c)  Price(s) and volume(s)                    Price(s)           Volume(s) 
                                        106.85 pence per      10,000 Ordinary 
                                        Ordinary Share        Shares 
 
d)  Aggregated information              N/A 
 
    - Aggregated volume 
 
    - Price 
 
e)  Date of the transaction             29 November 2017 
f)  Place of the transaction            London Stock Exchange, AIM 
 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker)                                     [e-mail] 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

November 30, 2017 08:57 ET (13:57 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.